Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group. Chaparro M, et al. Among authors: legido j. Aliment Pharmacol Ther. 2018 Oct;48(8):839-851. doi: 10.1111/apt.14930. Aliment Pharmacol Ther. 2018. PMID: 30281832
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-Sanromán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, Fe García-Sepulcre M, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Calafat M, et al. J Crohns Colitis. 2022 Jul 14;16(6):946-953. doi: 10.1093/ecco-jcc/jjab213. J Crohns Colitis. 2022. PMID: 34864947
Systematic review: the adverse effects of sodium phosphate enema.
Mendoza J, Legido J, Rubio S, Gisbert JP. Mendoza J, et al. Among authors: legido j. Aliment Pharmacol Ther. 2007 Jul 1;26(1):9-20. doi: 10.1111/j.1365-2036.2007.03354.x. Aliment Pharmacol Ther. 2007. PMID: 17555417 Free article. Review.
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
Taxonera C, Ponferrada Á, Bermejo F, Riestra S, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Alba C, Gisbert JP; SEGURTB study group from GETECCU. Taxonera C, et al. J Crohns Colitis. 2017 Jul 1;11(7):792-800. doi: 10.1093/ecco-jcc/jjx022. J Crohns Colitis. 2017. PMID: 28333182 Free article.
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.
Taxonera C, Ponferrada Á, Riestra S, Bermejo F, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Rivero M, Fernandez-Salazar L, Nantes Ó, Merino O, Alba C, Gisbert JP; CONVERT study group from GETECCU. Taxonera C, et al. J Crohns Colitis. 2018 Nov 15;12(11):1270-1279. doi: 10.1093/ecco-jcc/jjy104. J Crohns Colitis. 2018. PMID: 30052856
Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L, Muñoz F, Barrio J, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, Fernández N, Sánchez-Ocaña R, Joao D, Santos F. Fernández-Salazar L, et al. Among authors: legido j. Scand J Gastroenterol. 2016;51(2):186-95. doi: 10.3109/00365521.2015.1070900. Epub 2015 Jul 22. Scand J Gastroenterol. 2016. PMID: 26200929
Bone metabolism changes in patients with inflammatory bowel disease.
Legido J, Gisbert JP, Pajares JM, Maté J. Legido J, et al. Rev Esp Enferm Dig. 2005 Nov;97(11):815-29. doi: 10.4321/s1130-01082005001100006. Rev Esp Enferm Dig. 2005. PMID: 16438625 Free article. Review. English, Spanish. No abstract available.
Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis.
Fernández-Salazar L, Barrio J, Muñoz F, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, González-Redondo G, Fernández N, Santos F, Sánchez-Ocaña R, Joao D; ACAD (Asociación Castellana de Aparato Digestivo) Researchers. Fernández-Salazar L, et al. Among authors: legido j. Rev Esp Enferm Dig. 2015 Sep;107(9):527-33. Rev Esp Enferm Dig. 2015. PMID: 26334458 Free article.
33 results